We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.6M
AUM Growth
-$2.33B
Cap. Flow
-$744M
Cap. Flow %
-28,550.23%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 6.33%
2 Energy 0.47%
3 Consumer Discretionary 0.36%
4 Industrials 0.15%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALTO icon
201
Alto Ingredients
ALTO
$338M
$320 0.01%
22,900
-16,600
-42% -$312K
MDCO
202
PUT
DELISTED
Medicines Co
MDCO
$315 0.01%
141
-43
-23% -$1.09K
SLXP
203
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$312 0.01%
2,000
-47,403
-96% -$6.87M
HZNP
204
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$296 0.01%
241
+22
+10% +$256
HSTO
205
DELISTED
Histogen Inc. Common Stock
HSTO
$294 0.01%
+240
New +$345K
ALIM
206
DELISTED
Alimera Sciences
ALIM
$271 0.01%
3,333
-3,334
-50% -$285K
CPXX
207
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$271 0.01%
107,129
-234,495
-69% -$642K
ALIM
208
PUT
DELISTED
Alimera Sciences
ALIM
$266 0.01%
33
– –
WINT
209
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$262 0.01%
102
+3
+3% +$72
MDVN
210
PUT
DELISTED
MEDIVATION, INC.
MDVN
$257 0.01%
+52
New +$2.21K
AMT icon
211
PUT
American Tower
AMT
$83.5B
$234 0.01%
+25
New +$2.38K
BAXS
212
DELISTED
BAXANO SURGICAL INC COM STK (DE)
BAXS
$232 0.01%
+1,269,646
New +$519K
CARM
213
DELISTED
Carisma Therapeutics
CARM
$223 0.01%
1,000
-6,199
-86% -$1.47M
ALT icon
214
CALL
Altimmune
ALT
$568M
$219 0.01%
+4
New +$2.09K
IPCI
215
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$207 0.01%
+69
New +$1.99K
CERE
216
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$205 0.01%
62,500
-123,108
-66% -$582K
LSTA icon
217
CALL
Lisata Therapeutics
LSTA
$9.93M
$192 0.01%
+2
New +$1.75K
TNXP icon
218
CALL
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
EYPT icon
219
CALL
EyePoint Inc
EYPT
$999M
$155 0.01%
35
– –
LSTA icon
220
PUT
Lisata Therapeutics
LSTA
$9.93M
$145 0.01%
2
-5
-71% -$4.38K
ATHX
221
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$142 0.01%
41
-5
-11% -$192
KERX
222
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$138 0.01%
+100
New +$1.53K
INSM icon
223
Insmed
INSM
$22.4B
$131 0.01%
+10,000
New +$151K
ANTH
224
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$131 0.01%
85
+34
+67% +$715
SEEL
225
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6M, down 100% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $744M in Q3 2014, closing 85 positions and reducing 62 holdings. Its most notable exit was Weyerhaeuser, an estimated $64.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Acadia Healthcare worth $16.4K.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4K.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6M portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value fell 100% quarter-over-quarter to $2.6M.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.